Navigation Links
Multiple sclerosis -- antihypertensive drug ameliorate inflammation in the brain
Date:7/28/2010

Researchers in Heidelberg and Stanford have discovered a new signalling pathway of brain cells that explains how widely used antihypertensive drugs could keep inflammation in multiple sclerosis (MS) in check. The peptide angiotensin not only raises blood pressure but also activates the immunological messenger substance TGF beta on a previously unknown communication pathway in the brain. The study was conducted by Professor Lawrence Steinman at Stanford University in California together with the group of Professor Platten and published in the "Journal of Clinical Investigation". The Heidelberg team of researchers consisted of Dr. Tobias Lanz, lead author of the study and Professor Dr. Michael Platten, lead author of the previous study on that topic. Professor Platten is the senior consultant at the Department of Neurooncology at Heidelberg University Hospital and the head of the Helmholtz University Young Investigators Group "Experimental Neuroimmunology" at the German Cancer Research Center (DKFZ) in Heidelberg.

Angiotensin II is known as a molecule that regulates blood pressure. Drugs that block the angiotensin receptors, (AT1R blockers), are prescribed to millions of people to lower high blood pressure. These receptors have now also been found on numerous organs and cells that have nothing to do with regulating blood pressure, for example on the T cells of the immune system. These are immune cells that are involved in autoimmune reactions and chronic-inflammatory diseases such as MS. MS is characterized by multifocal areas of inflammation in the brain and spinal cord that lead to paralysis and other neurological symptoms.

Paralysis resolved in an animal model

The scientists working with Professor Platten showed in a mouse model that angiotensin II promotes inflammation in the brain and spinal cord. When the angiotensin receptors, i.e. the sites where angiotensin docks onto cells and can develop its effect, were block
'/>"/>

Contact: Prof. Dr. med. Michael Platten
michael.platten@med.uni-heidelberg.de
062-215-66804
University Hospital Heidelberg
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
2. University at Buffalo launches clinical trial of new multiple sclerosis treatment
3. Clinical Trial Testing New Multiple Sclerosis Treatment to Launch in Buffalo
4. Cancer and Multiple Sclerosis Survivor Martin Smith's 3,000-mile Bicycle Ride Benefits Cancer Research
5. Can multiple sclerosis attacks be minimized in a war zone?
6. Quincy Bioscience Sponsors Multiple Sclerosis (MS) Scholarship Program
7. 96 percent of vasectomy patients cleared without need for multiple semen samples
8. Protein lets brain repair damage from multiple sclerosis, other disorders
9. Simple eye test measures damage from multiple sclerosis, UT Southwestern researchers find
10. Projects In Knowledge Launches Free iPhone App of Living Medical Textbook Neurology: Multiple Sclerosis 2010 Edition
11. $1.9 million grant to help UCF find multiple sclerosis nerve-ana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... New York, NY (PRWEB) May 20, 2013 ... to protecting the rights of victims injured by defective ... South Dakota man who alleges that use of the ... The suit was filed on April 30, 2013, ... of Louisiana (Case No. 6:13-cv-0888), where it is one ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Mirena ... in the multidistrict litigation recently established in U.S. District ... reports. According to court records, the litigation’s first ... time appointments to Plaintiff’s leadership positions were discussed. ... in the Southern District of New York, all of ...
(Date:5/20/2013)... Salt Lake Community College’s Know Greater Heroes program ... winners for 2013. As part of the award, the ... is a leadership training program that involves SLCC athletes who ... eat right, be active, and avoid drugs and alcohol. , ... program each year, and visit more than 30 schools each ...
(Date:5/20/2013)... The judge overseeing pretrial proceedings in ... specifically for female lawyers to be included in a ... Group LLP acknowledges the judge’s request, noting that its ... providing information on Mirena side effects and how to ... the addition of some female lawyers to the committee. ...
(Date:5/20/2013)... 2013 While Huntington,s disease (HD) is currently ... disease-modifying therapies in development may slow or minimize ... depends upon the identification of reliable and sensitive ... these biomarkers may eventually be used as outcome ... helpful to monitor changes during the time prior ...
Breaking Medicine News(10 mins):Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Reports on First Status Conference in Federal Mirena Litigation 3Health News:SLCC Know Greater Heroes Program Named to Select 25 2Health News:SLCC Know Greater Heroes Program Named to Select 25 3Health News:Mirena IUD Lawsuit Update: Judge Calls for More Input from Female Lawyers, Notes Rottenstein Law Group LLP 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 2Health News:Leading researchers report on the elusive search for biomarkers in Huntington's disease 3
... Cleaners Proven to Protect and Even Improve Health, ... homes is,increasingly contaminated and polluted, and now studies have ... not only allergy and asthma,symptoms but also a variety ... clots., Studies are emerging that prove poor indoor ...
... the type diagnosed in Sen. Edward Kennedy , , MONDAY, ... is showing promise against the same general type of ... reporting. , The vaccine, when given with chemotherapy, more ... tumors. Kennedy was diagnosed last month with a malignant ...
... The discovery of new genetic mutations involved in inflammatory ... these common conditions, two scientists told the annual conference ... 2 June). , Dr.Alexandra ... Netherlands, and Dr. Eleonora Festen, from the University of ...
... ST. PETERSBURG, Fla., June 2 The Advanced,Wound Management ... announced,today that its negative pressure wound therapy (NPWT) products ... areas included in the,first phase of the competitive bidding ... (CMS) in the U.S. The program, which is,scheduled to ...
... family of CCRCs with expansion into Alabama;,Community to ... June 2 ACTS Retirement-Life,Communities, a premier not-for-profit ... its acquisition of Carlton Cove, a,continuing care retirement ... renamed Magnolia Trace and become the 19th ACTS,continuing ...
... the body,s own tissues and organs, wreaking havoc and ... of these diseases are so obscure, no effective treatment ... Weizmann Institute scientists have developed a method that in ... diseases effectively without necessarily knowing their exact cause. Their ...
Cached Medicine News:Health News:Studies Find Poor Indoor Air Quality Can Lead to Major Health Problems 2Health News:Studies Find Poor Indoor Air Quality Can Lead to Major Health Problems 3Health News:Vaccine May Boost Survival of Brain Cancer Patients 2Health News:Vaccine May Boost Survival of Brain Cancer Patients 3Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 2Health News:Discovery of new family of genetic mutations involved in inflammatory intestinal disease 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 2Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 3Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 4Health News:Smith & Nephew Negative Pressure Wound Therapy Products To Be Available To Patients Through the Medicare Part B Competitive Bidding Process 5Health News:ACTS Retirement-Life Communities Completes Carlton Cove Acquisition 2Health News:Weizmann Institute scientists develop a new approach to treating autoimmune disease 2
(Date:5/20/2013)... , BERLIN and ... Arthroscopy Devices Market to 2018 ... Invasive Procedures to Drive Future Growth" looks at the ... six arthroscopy device market segments: arthroscopes, arthroscopy shavers, arthroscopy ... systems, and arthroscopy visualization systems. The report provides comprehensive ...
(Date:5/20/2013)... 2013  Rhythm announced today the presentation of results ... of gastroparesis symptoms among diabetic patients in the U.S. ... among patients with both type 1 and type 2 ... with the more common type 2 disease. ... Associate Professor of Medicine at Harvard Medical School and ...
(Date:5/20/2013)... May 20, 2013  AbbVie (NYSE: ... Phase 3 clinical study called SONAR (Study Of ... of the investigational compound atrasentan - when added to ... in patients with stage 2 to 4 chronic ... is a large, multinational, double-blind, placebo-controlled clinical study ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... Inc. (Nasdaq: MAPP ) today announced that the ... Stifel Nicolaus Healthcare Conference Thursday, September 8, at ... Sciences Conference Wednesday, September 21, at 9:30 a.m. ET in ... will be available on the Investor Relations section of MAP ...
... THOUSAND OAKS, Calif., Sept. 6, 2011 Amgen (NASDAQ: ... on Thursday, Sept. 8, 2011, at The New York Palace ... Time. Arvind Sood, vice president of Investor Relations at Amgen, ... from the Events Calendar on Amgen,s website, www.amgen.com , ...
Cached Medicine Technology:
...
Designed to minimize emblolic debris in SVGs and carotids...
... the ability of interventional cardiologists and ... disease, and provides non-interventional cardiologists with ... treatment of patients who have become ... provides a noninvasive, atraumatic treatment for ...
... petite titanium model comes with ... lumen) and is our smallest ... offer larger lumen equivalency while ... lumen offset-tip catheters are available ...
Medicine Products: